About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(CMV-cre)1Ipc
transgene insertion 1, I Pierre Chambon
MGI:2177165
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Capns1tm2Pag/Capns1tm2.1Pag
Tg(CMV-cre)1Ipc/0
involves: 129P2/OlaHsd * C57BL/6 * SJL MGI:3712966
cn2
Fgfr3tm2Llm/Fgfr3+
Tg(CMV-cre)1Ipc/?
involves: 129S2/SvPas * C57BL/6 * SJL MGI:5426512
cn3
Artm1Ska/Y
Tg(CMV-cre)1Ipc/?
involves: C57BL/6 * CBA MGI:2681522


Genotype
MGI:3712966
cn1
Allelic
Composition
Capns1tm2Pag/Capns1tm2.1Pag
Tg(CMV-cre)1Ipc/0
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Capns1tm2.1Pag mutation (0 available); any Capns1 mutation (19 available)
Capns1tm2Pag mutation (0 available); any Capns1 mutation (19 available)
Tg(CMV-cre)1Ipc mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• few pups are recovered at E13.5 (J:110138)
• few pups are recovered at E13.5 (J:110138)




Genotype
MGI:5426512
cn2
Allelic
Composition
Fgfr3tm2Llm/Fgfr3+
Tg(CMV-cre)1Ipc/?
Genetic
Background
involves: 129S2/SvPas * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Fgfr3tm2Llm mutation (0 available); any Fgfr3 mutation (10 available)
Tg(CMV-cre)1Ipc mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• severe dwarfism (J:183772)
• severe dwarfism (J:183772)

skeleton
• reduced width of skull (J:183772)
• reduced width of skull (J:183772)
• narrow trunk (J:183772)
• narrow trunk (J:183772)
• osteoclasts per bone area are increased (J:183772)
• osteoclast surface area/bone surface area is increased (J:183772)
• osteoclasts per bone area are increased (J:183772)
• osteoclast surface area/bone surface area is increased (J:183772)
• fewer subchondral trabeculae (J:183772)
• trabeculae only partially mineralized (J:183772)
• more abundant collagen deposition (J:183772)
• significantly lower bone volume/trabecular volume in distal metaphysis of the femur (J:183772)
• fewer subchondral trabeculae (J:183772)
• trabeculae only partially mineralized (J:183772)
• more abundant collagen deposition (J:183772)
• significantly lower bone volume/trabecular volume in distal metaphysis of the femur (J:183772)
• smaller hypertrophic mineralization zone (J:183772)
• smaller hypertrophic mineralization zone (J:183772)
• reduced size of epiphysis (J:183772)
• reduced size of epiphysis (J:183772)
• defect in mineralization of calcified cartilage and primary spongiosa (J:183772)
• defect in mineralization of calcified cartilage and primary spongiosa (J:183772)

craniofacial
• reduced width of skull (J:183772)
• reduced width of skull (J:183772)

hematopoietic system
• osteoclasts per bone area are increased (J:183772)
• osteoclast surface area/bone surface area is increased (J:183772)
• osteoclasts per bone area are increased (J:183772)
• osteoclast surface area/bone surface area is increased (J:183772)

immune system
• osteoclasts per bone area are increased (J:183772)
• osteoclast surface area/bone surface area is increased (J:183772)
• osteoclasts per bone area are increased (J:183772)
• osteoclast surface area/bone surface area is increased (J:183772)




Genotype
MGI:2681522
cn3
Allelic
Composition
Artm1Ska/Y
Tg(CMV-cre)1Ipc/?
Genetic
Background
involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Artm1Ska mutation (0 available); any Ar mutation (13 available)
Tg(CMV-cre)1Ipc mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
adipose tissue
• wet weights of subcutaneous, infrarenal and intraperitoneal white adipose tissues are significantly increased by 30 weeks of age (J:85484)
• serum lipid parameters and food intake remain unaffected (J:85484)
• wet weights of subcutaneous, infrarenal and intraperitoneal white adipose tissues are significantly increased by 30 weeks of age (J:85484)
• serum lipid parameters and food intake remain unaffected (J:85484)

endocrine/exocrine glands
• inguinal testes (J:85484)
• inguinal testes (J:85484)
• small degenerating testes (J:85484)
• small degenerating testes (J:85484)

growth/size/body
• after 10 weeks of age, the growth of males increased dramatically (J:85484)
• by 12 weeks of age, the body weights of mutant males are higher than those of wild-type males (J:85484)
• after 10 weeks of age, the growth of males increased dramatically (J:85484)
• by 12 weeks of age, the body weights of mutant males are higher than those of wild-type males (J:85484)
• by 30 weeks of age males are obese (J:85484)
• by 30 weeks of age males are obese (J:85484)
• growth retardation in males through 10 weeks of age (J:85484)
• growth retardation in males through 10 weeks of age (J:85484)

renal/urinary system
• clitoris-like phallus instead of a penis and scrotum (J:85484)
• clitoris-like phallus instead of a penis and scrotum (J:85484)

reproductive system
• inguinal testes (J:85484)
• inguinal testes (J:85484)
• small degenerating testes (J:85484)
• small degenerating testes (J:85484)
• clitoris-like phallus instead of a penis and scrotum (J:85484)
• clitoris-like phallus instead of a penis and scrotum (J:85484)
• vagina with a blind end (J:85484)
• vagina with a blind end (J:85484)
• feminization of external appearance, including a blind vagina and a clitoris-like phallus, with absence of internal male and female reproductive organs, except for atrophic testes (J:85484)
• no ovaries or uteri are observed (J:85484)
• feminization of external appearance, including a blind vagina and a clitoris-like phallus, with absence of internal male and female reproductive organs, except for atrophic testes (J:85484)
• no ovaries or uteri are observed (J:85484)
• lower levels of androgens (J:85484)
• estradiol levels typical for a male (J:85484)
• lower levels of androgens (J:85484)
• estradiol levels typical for a male (J:85484)

cardiovascular system
• in response to angiotensin-II stimulation, male homozygotes show a smaller increase in the cross-sectional area of cardiomyocytes relative to wild-type males (J:101049)
• in response to angiotensin-II stimulation, male homozygotes show a smaller increase in the cross-sectional area of cardiomyocytes relative to wild-type males (J:101049)
• after 6 weeks of age, male homozygotes show a significantly reduced cross-sectional area of cardiomyocytes in LV tissues relative to wild-type males (J:101049)
• after 6 weeks of age, male homozygotes show a significantly reduced cross-sectional area of cardiomyocytes in LV tissues relative to wild-type males (J:101049)
• after 6 weeks of age, male homozygotes exhibit a cardiac size reduction relative to wild-type males (J:101049)
• in response to angiotensin-II stimulation, male homozygotes show a smaller increase in cardiac size relative to wild-type males (J:101049)
• after 6 weeks of age, male homozygotes exhibit a cardiac size reduction relative to wild-type males (J:101049)
• in response to angiotensin-II stimulation, male homozygotes show a smaller increase in cardiac size relative to wild-type males (J:101049)
• male homozygotes display no significant differences in basal levels of systolic blood pressure and heart rate; however, after 6 weeks of age, male homozygotes show a significant reduction in HW/BW ratio relative to wild-type males (J:101049)
• in response to angiotensin-II stimulation, male homozygotes display a smaller increase in HW/BW ratio relative to wild-type males (J:101049)
• male homozygotes display no significant differences in basal levels of systolic blood pressure and heart rate; however, after 6 weeks of age, male homozygotes show a significant reduction in HW/BW ratio relative to wild-type males (J:101049)
• in response to angiotensin-II stimulation, male homozygotes display a smaller increase in HW/BW ratio relative to wild-type males (J:101049)
• after 6 weeks of age, male homozygotes display a reduced LV volume relative to wild-type males (J:101049)
• in response to angiotensin-II stimulation, male homozygotes exhibit an impaired hypertrophic response with lower cardiac LV volumes that is partly associated with reduced activation of mitogen-activated protein kinases 1/2 and 5 (J:101049)
• after 6 weeks of age, male homozygotes display a reduced LV volume relative to wild-type males (J:101049)
• in response to angiotensin-II stimulation, male homozygotes exhibit an impaired hypertrophic response with lower cardiac LV volumes that is partly associated with reduced activation of mitogen-activated protein kinases 1/2 and 5 (J:101049)
• after 6 weeks of age, male homozygotes exhibit a reduced left ventricular (LV) wall thickness relative to wild-type males (J:101049)
• in response to angiotensin-II stimulation, male homozygotes show a lower increase in LV wall thickening relative to wild-type males (J:101049)
• after 6 weeks of age, male homozygotes exhibit a reduced left ventricular (LV) wall thickness relative to wild-type males (J:101049)
• in response to angiotensin-II stimulation, male homozygotes show a lower increase in LV wall thickening relative to wild-type males (J:101049)
• in response to angiotensin-II stimulation, 25-wk-old male homozygotes display an exacerbated interstitial fibrosis in the left ventricular area relative to age-matched wild-type males (J:101049)
• enhanced angiotensin-II-mediated cardiac interstitial fibrosis is associated with up-regulation of collagen I and III gene expression and enhanced cardiac transforming growth factor-beta1 and Smad2 activation (J:101049)
• in response to angiotensin-II stimulation, 25-wk-old male homozygotes display an exacerbated interstitial fibrosis in the left ventricular area relative to age-matched wild-type males (J:101049)
• enhanced angiotensin-II-mediated cardiac interstitial fibrosis is associated with up-regulation of collagen I and III gene expression and enhanced cardiac transforming growth factor-beta1 and Smad2 activation (J:101049)
• at 25 weeks, male homozygotes exhibit a normal left ventricular fractional shortening (a marker of systolic function) relative to wild-type males (J:101049)
• however, in response to angiotensin-II stimulation, male homozygotes display a significantly attenuated LV systolic function relative to wild-type males (J:101049)
• at 25 weeks, male homozygotes exhibit a normal left ventricular fractional shortening (a marker of systolic function) relative to wild-type males (J:101049)
• however, in response to angiotensin-II stimulation, male homozygotes display a significantly attenuated LV systolic function relative to wild-type males (J:101049)

muscle
• in response to angiotensin-II stimulation, male homozygotes show a smaller increase in the cross-sectional area of cardiomyocytes relative to wild-type males (J:101049)
• in response to angiotensin-II stimulation, male homozygotes show a smaller increase in the cross-sectional area of cardiomyocytes relative to wild-type males (J:101049)
• after 6 weeks of age, male homozygotes show a significantly reduced cross-sectional area of cardiomyocytes in LV tissues relative to wild-type males (J:101049)
• after 6 weeks of age, male homozygotes show a significantly reduced cross-sectional area of cardiomyocytes in LV tissues relative to wild-type males (J:101049)
• at 25 weeks, male homozygotes exhibit a normal left ventricular fractional shortening (a marker of systolic function) relative to wild-type males (J:101049)
• however, in response to angiotensin-II stimulation, male homozygotes display a significantly attenuated LV systolic function relative to wild-type males (J:101049)
• at 25 weeks, male homozygotes exhibit a normal left ventricular fractional shortening (a marker of systolic function) relative to wild-type males (J:101049)
• however, in response to angiotensin-II stimulation, male homozygotes display a significantly attenuated LV systolic function relative to wild-type males (J:101049)

Mouse Models of Human Disease
OMIM ID Ref(s)
Androgen Insensitivity Syndrome; AIS 300068 J:85484
Obesity 601665 J:85484





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory